Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 4 2Phase 1 2Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Carcinoma, Hepatocellular 15Small Cell Lung Carcinoma 11Triple Negative Breast Neoplasms 9Neoplasms 8Colorectal Neoplasms 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Lung Neoplasms 5Carcinoma, Renal Cell 5Ovarian Neoplasms 4Carcinoma, Transitional Cell 3Carcinoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Melanoma 2Colonic Neoplasms 2Venous Thrombosis 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Rectal Neoplasms 1Radiation Pneumonitis 1Prostatic Neoplasms, Castration-Resistant 1Peritoneal Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Non-Small-Cell Lung 1

Interventions

Sorafenib 8durvalumab 4Cisplatin 4Gemcitabine 3Ethiodized Oil 3Doxorubicin 3Chemotherapy, Adjuvant 3Bevacizumab 3tremelimumab 2sodium thiosulfate 2phosphomannopentaose sulfate 2Watchful Waiting 2Talaporfin 2Radiofrequency Ablation 2Oxaliplatin 2Nivolumab 2Folfox protocol 2Celecoxib 2Capecitabine 2Analgesia, Patient-Controlled 2seocalcitol 1parecoxib 1nolatrexed 1linifanib 1lenvatinib 1ferumoxides 1ferric carboxymaltose 1contrast agent BR1 1cabozantinib 1brivanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Liver Neoplasms × atezolizumab × Clear all
NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest Therapeutics

Phase 3 Not yet recruiting
740 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡